Phase III trial of 196 patients shows stereotactic radiation targeting individual tumors significantly improved symptom burden and daily functioning compared with hippocampal-avoidance whole-brain radiation, without compromising survival.
Precision oncology has transformed brain metastases treatment from lung cancer, extending survival from 6-12 months to 3-5 years through targeted therapies, immunotherapy, and radiosurgery. With 100,000-200,000 annual cases in the US, multidisciplinary approaches now manage this once-terminal condition as a chronic disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07422168 |
Hyperbaric Oxygen Therapy for Treatment of Severe Radiation-Induced Complications |
COMPLETED | NA |
| NCT06888817 |
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases |
RECRUITING | PHASE3 |
| NCT05762172 |
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis |
COMPLETED | NA |
| NCT05124912 |
REMASTer: REcurrent Brain Metastases After SRS Trial |
RECRUITING | NA |
| NCT02819479 |
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) |
COMPLETED | PHASE2 |
| NCT02212964 |
Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2* |
COMPLETED | |
| NCT01651078 |
Laser Ablation After Stereotactic Radiosurgery |
COMPLETED | |
| NCT01201850 |
The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors |
TERMINATED | NA |
| NCT00285324 |
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis |
COMPLETED |
